KUR Stock Chart & Stats
€10.75
-€0.86(-9.68%)
At close: 4:00 PM EDT
€10.75
-€0.86(-9.68%)
Day’s Range― - ―
52-Week Range€6.15 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)64.00
Market Cap
€841.62M
Enterprise Value€480.17M
Total Cash (Recent Filing)€519.02M
Total Debt (Recent Filing)€24.45M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Oct 29, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.37
Shares Outstanding88,960,620
10 Day Avg. Volume0
30 Day Avg. Volume64
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.93Price Target Upside122.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.84
Revenue Forecast (FY)€85.26M
Bulls Say, Bears Say
Bulls Say
Early Commercial AdoptionCOMZIFTI has established an early commercial foothold, with meaningful product revenue, rapid prescription growth, and majority share of new patient starts in its target AML population. Broad coverage and preferred access could support durable adoption as the launch matures.
Clinical Pipeline StrengthPositive response data across ziftomenib and darlifarnib support the potential for a differentiated precision-oncology pipeline. Multiple targeted programs and disease settings diversify clinical opportunity and could expand Kura’s long-term product platform if pivotal studies confirm efficacy.
Development Funding RunwayManagement’s stated funding plan provides visibility for advancing the key ziftomenib AML program through the first pivotal readout. Kyowa Kirin payments supplement existing liquidity, supporting continued clinical execution and reducing immediate dependence on a new capital raise.
Bears Say
Persistent Operating LossesKura remains structurally unprofitable despite emerging product revenue and strong gross margin. Large operating expenses relative to the current revenue base mean commercial growth has not yet translated into earnings, leaving profitability dependent on substantial future scale or successful approvals.
Ongoing Cash BurnNegative operating and free cash flow indicate that development and commercial activities continue to consume substantial liquidity. The decline in cash since year-end reduces financial flexibility over time and increases reliance on collaboration receipts, funding resources, or future financing.
Long Clinical TimelinesImportant clinical value inflection points remain years away, extending the period in which Kura must fund research and commercial operations before definitive pivotal evidence arrives. Delayed readouts increase execution and outcome uncertainty and postpone potential expansion of the revenue base.
Kura Oncology News
KUR FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was €6.15 and its highest was €11.80 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is €841.62M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 18 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 12, 2026. The company reported -€0.687 earnings per share for the quarter, beating the consensus estimate of -€0.783 by €0.095.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.73.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,960,620 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -€0.687 in its last earnings report, beating expectations of -€0.783. Following the earnings report the stock price went up 1.182%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in DE:KUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.93 (122.63% Upside)
€23.93 (122.63% Upside)
Blogger Sentiment
Bullish
DE:KUR Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €1.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.41%
12-Months-Change
Fundamentals
Return on Equity
-207.18%
Trailing 12-Months
Asset Growth
-13.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
KUR Company Deck
KUR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial traction for COMZIFTI (notable revenue, majority share of new patient starts, high Q/Q growth in starts and prescriptions), robust clinical data across Ziftomenib and promising darlifarnib combination signals in multiple solid tumor settings. Financials show solid funding runway with Kyowa Kirin support but also reflect increased commercial spend, a declining cash balance since year‑end, and a YoY decline in collaboration revenue. Competitive noise around market share and the multi‑year timelines to pivotal readouts add uncertainty. Overall, positive operational and clinical momentum is balanced against near‑term financial and competitive considerations.View all DE:KUR earnings summariesKUR Stock 12 Month Forecast
Average Price Target
€23.93
▲(122.63% Upside)
Technical Analysis
Geron
―
CytomX Therapeutics
―
Zentalis Pharmaceuticals
―
Oric Pharmaceuticals
―
Prelude Therapeutics
―